Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Atrium Therapeutics, Inc. Common Stock

RNA

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Last trade $6.58
Day change +$0.15 (+2.33%)
Day range $6.42 – $6.99
Volume 234,610
Market cap $139M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$138.7M
Price / earnings
—
Price / book
0.68×
Price / sales
2.76×
EV / sales
1.87×
EV / EBITDA
-2.05×

Profitability

Earnings per share
-$1.91
Return on assets
-15.58%
Return on equity
-20.06%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.46×
Quick ratio
10.46×
Cash ratio
1.81×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$62.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RNA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$15.32M$3M$19.64M$860K$12.48M$3.85M$1.57M$2.97M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$15.32M$3M$19.64M$860K$12.48M$3.85M$1.57M$2.97M
Selling, general and administrative$8.15M$10.28M$20.26M$88.74M$46.33M$36.86M$33.6M$28.34M
Research and development$13.8M$15.34M$16.66M$166.6M$154.95M$138.13M$99.49M$95.63M
Total operating expenses$21.95M$25.62M$36.92M$255.34M$201.28M$174.99M$133.09M$123.96M
Operating income-$6.63M-$22.62M-$17.28M-$254.48M-$188.81M-$171.14M-$131.52M-$120.99M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.27M-$20.19M-$16.63M-$237.1M-$174.44M-$157.32M-$115.77M-$102.26M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.27M-$20.19M-$16.63M-$237.1M-$174.44M-$157.32M-$115.77M-$102.26M
Net income attributable to common shareholders-$4.27M-$20.19M-$16.63M-$237.1M-$174.44M-$157.32M-$115.77M-$102.26M
EBITDA-$6.28M-$22.28M-$17.13M-$252.98M-$187.75M-$170.33M-$130.73M-$120.25M
Basic earnings per share-$0.25-$1.18-$0.97-$1.54-$1.27-$1.21-$0.90-$0.79
Diluted earnings per share-$0.25-$1.18-$0.97-$1.54-$1.27-$1.21-$0.90-$0.79

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO

Monteverde & Associates PC, a class action securities firm, is investigating four proposed mergers: The Brand House Collective's sale to Bed Bath & Beyond, Avidity Biosciences' acquisition by Novartis for $72 per share, NorthWestern Energy Group's sale to Black Hills Corp, and Two Harbors Investment Corp's merger with UWM Holdings Corporation. The firm is seeking shareholders with concerns about these transactions ahead of upcoming shareholder votes.

Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.